These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 16180963)

  • 21. Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid.
    Seabury SA; Goldman DP; Kalsekar I; Sheehan JJ; Laubmeier K; Lakdawalla DN
    Am J Manag Care; 2014 Feb; 20(2):e52-60. PubMed ID: 24738555
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antipsychotic use at adult ambulatory care visits by patients with mental health disorders in the United States, 1996-2003: national estimates and associated factors.
    Sankaranarayanan J; Puumala SE
    Clin Ther; 2007 Apr; 29(4):723-41. PubMed ID: 17617297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dosing atypical antipsychotics.
    Cutler A; Ball S; Stahl SM
    CNS Spectr; 2008 May; 13(5 Suppl 9):1-16. PubMed ID: 18496483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outpatient antipsychotic treatment and inpatient costs of schizophrenia.
    Marcus SC; Olfson M
    Schizophr Bull; 2008 Jan; 34(1):173-80. PubMed ID: 17578893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In the aftermath of CATIE: how should administrators value atypical antipsychotic medications?
    Luchins DJ
    Adm Policy Ment Health; 2006 Sep; 33(5):541-3. PubMed ID: 16688482
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medicaid's prior authorization program and access to atypical antipsychotic medications.
    Polinski JM; Wang PS; Fischer MA
    Health Aff (Millwood); 2007; 26(3):750-60. PubMed ID: 17485754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Importance of open access to atypical antipsychotics for the treatment of schizophrenia and bipolar disorder: a European perspective.
    Altamura AC; Armadoros D; Jaeger M; Kernish R; Locklear J; Volz HP
    Curr Med Res Opin; 2008 Aug; 24(8):2271-82. PubMed ID: 18588748
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Schizophrenia: multi-attribute utility theory approach to selection of atypical antipsychotics.
    Bettinger TL; Shuler G; Jones DR; Wilson JP
    Ann Pharmacother; 2007 Feb; 41(2):201-7. PubMed ID: 17311836
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.
    Obradovic M; Mrhar A; Kos M
    Int J Clin Pract; 2007 Dec; 61(12):1979-88. PubMed ID: 17997804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mood stabilizers and atypical antipsychotics: bimodal treatments for bipolar disorder.
    Ketter TA; Nasrallah HA; Fagiolini A
    Psychopharmacol Bull; 2006; 39(1):120-46. PubMed ID: 17065977
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatments for late-life bipolar disorder.
    Aziz R; Lorberg B; Tampi RR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):347-64. PubMed ID: 17296540
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The case for long-acting antipsychotic agents in the post-CATIE era.
    Nasrallah HA
    Acta Psychiatr Scand; 2007 Apr; 115(4):260-7. PubMed ID: 17355516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The unintended (and costly) effects due to the introduction of an unrestricted reimbursement policy for atypical antipsychotic medications in a Canadian public prescription drug program: 1996/97 to 2005/06.
    O'Reilly DJ; Goeree RA; Tarride JE; James C; Parfrey PS
    Can J Clin Pharmacol; 2009; 16(2):e346-59. PubMed ID: 19531813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Containing cost despite the cost.
    Farley JF
    Med Care; 2010 Jan; 48(1):1-3. PubMed ID: 19956078
    [No Abstract]   [Full Text] [Related]  

  • 37. The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia.
    Becker MA; Young MS; Ochshorn E; Diamond RJ
    Adm Policy Ment Health; 2007 May; 34(3):307-14. PubMed ID: 17211716
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics.
    Vogt WB; Joyce G; Xia J; Dirani R; Wan G; Goldman DP
    Health Aff (Millwood); 2011 Dec; 30(12):2346-54. PubMed ID: 22147863
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduced drug coverage saved Medicaid 'pennies,' cost state 'pounds'.
    Am J Hosp Pharm; 1994 Nov; 51(21):2622. PubMed ID: 7856574
    [No Abstract]   [Full Text] [Related]  

  • 40. Medicaid prior authorization policies and imprisonment among patients with schizophrenia.
    Goldman D; Fastenau J; Dirani R; Helland E; Joyce G; Conrad R; Lakdawalla D
    Am J Manag Care; 2014 Jul; 20(7):577-86. PubMed ID: 25295404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.